As grim as the likely loss of the U.K. market for the drug may be, Lilly is far from helpless, and the damage, while notable, might not actually drag on its growth by a noticeable amount if its ...
Eli Lilly's Alzheimer's drug Kisunla, under late-stage trials, shows promising interim results with a gradual dosing schedule, reducing serious brain swelling cases. The trial, which is under review ...